Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 8551 - 8575 of 9280 in total
ASP-2138 is a bispecific antibody directed against CLDN18.2 and T cell receptor complex CD3
Investigational
CPO-107 is a CD20-CD47 bispecific fusion protein
Investigational
GTB-3550 is a single-chain, tri-specific scFv recombinant fusion protein conjugate composed of the variable regions of the heavy and light chains of anti-CD16 and anti-CD33 antibodies and a modified form of Interleukin 15 (IL-15).
Investigational
ACTX-401 is a single-stranded, non-replicating recombinant adeno-associated viral vector serotype 9 containing the human immunoglobulin u-binding protein 2 cDNA.
Investigational
Investigational
Autologous pancreatic islet therapy involves isolating the patient's own insulin-producing cells.
Investigational
Investigational
Investigational
SIG-205 is a Cultured human retinal pigment epithelial cells (ARPE-19) genetically modified with a non-viral vector to express human native alpha-L-iduronidase enzyme (hIDUA), encapsulated within two-layer modified alginate spheres
Investigational
OSSM-007 consists of interferon-gamma primed allogeneic mesenchymal stem cells.
Investigational
Ergidina is a recombinant human minibody against complement component C5 fused with RGD-motif.
Investigational
PA3-17 is CD7-directed chimeric antigen receptor (CAR) T-cell therapy.
Investigational
TRK-001 is an autologous regulatory T-cell therapy. It is being investigated for the prevention of graft rejection following solid organ transplantation.
Investigational
ETX101 is a non-replicating recombinant adeno associated viral vector, serotype 9, designed to promote increased transcription of SCN1A gene.
Investigational
PBGM01 is a non-replicating recombinant adeno-associated virus serotype hu68 vector, which contains human GLB1 transgene encoding the galactosidase beta 1 enzyme.
Investigational
CTR-107 is a synthetic targeted growth factor. It is being investigated for the treatment of familial exudative vitreoretinopathy.
Investigational
NGN-401 is a recombinant serotype 9 adeno-associated virus (AAV) encoding an intron encoding a miRNA generating sequence, complementary miRNA binding sites and a full-length human methyl cytosine binding protein 2 (MECP2). Developed by Neurogene Inc., it is being investigated for the treatment of Rett syndrome.
Investigational
FCR001 is a somatic cell therapy product containing hematopoietic progenitor cells (HPC), Facilitating Cells (FC), and alpha beta T cells.
Investigational
M1-c6v1 is a recombinant oncolytic virus.
Investigational
TSHA-102 is a recombinant serotype 9 adeno-associated virus encoding a codon-optimized human MECP2 gene.
Investigational
Perenostobart is an alpha-CD39 IgG4 monoclonal antibody.
Investigational
ECT204 is an autologous T-cell therapy whereby T cells are genetically modified to target tumor-specific antigens.
Investigational
Displaying drugs 8551 - 8575 of 9280 in total